News

  1. LIfT BioSciences And Minaris Regenerative Medicine Enter Into A Development And Manufacturing Partnership For N-LIfT Allogeneic Neutrophil Based Cell Therapy 2/16/2023

    LIfT BioSciences, a pioneering pre-clinical stage company moving into first-in-human trials with an allogeneic neutrophil progenitor based cell therapy, and Minaris Regenerative Medicine GmbH, a leading global contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a development and manufacturing partnership for N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy for the treatment of various cancer indications, including Pancreatic Cancer, Lung Cancer and other solid tumours.

  2. Windgap Medical Appoints Aaron Mann As CEO, Michael Samar As CFO 2/13/2023

    Both bring significant industry tenure and experience to their roles, and with Windgap Co-Founder Brent Buchine, will lead the company's continued growth in the field of complex injectable drug delivery solutions.

  3. Elektrofi Announces Collaboration With Thermo Fisher Scientific To Strengthen Manufacturing Capabilities For Future Clinical Trials 2/7/2023

    Elektrofi, a biotechnology company focused on drug formulation and delivery innovations, today announced a strategic contract manufacturing agreement with Thermo Fisher Scientific to support clinical manufacture of Elektrofi’s breakthrough ultra-high concentration subcutaneous products.

  4. Phillips-Medisize Expands Product Portfolio With Launch Of A Pen Injector Platform Designed To Lower Pharma Costs, Risks And Market Barriers 2/1/2023

    Phillips-Medisize, a Molex company and leader in the design and manufacture of drug delivery, diagnostic and MedTech devices, has expanded its product portfolio with the introduction of a disposable pen injector.

  5. Lilly Plans To Invest Additional $450M At Manufacturing Site In Research Triangle Park 1/24/2023

    Eli Lilly and Company (NYSE: LLY) today announced plans to invest an additional $450 million and create at least 100 new jobs to expand its manufacturing capacity at the company's Research Triangle Park facility. The expansion includes additional parenteral filling, device assembly and packaging capacity to support an increased demand for Lilly's incretin products that treat diabetes.

  6. Stevanato Group Collaborates With Transcoject To Provide Pre-Fillable Syringe Polymer Options For Pharma 1/24/2023

    Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, announced its latest collaboration with Transcoject GmbH, a medical device and pharma packaging solutions company.

  7. Parenteral Drug Association Announces New EU GMP Annex 1 Implementation Interest Group 1/20/2023

    PDA is pleased to announce the formation of the Annex 1 Implementation Interest Group, which will begin meeting in February.

  8. Catalent And Ethicann Sign Development And License Agreement For New Fast-Dissolve Cannabinoid-Based Treatments 1/12/2023

    Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities, and Ethicann Pharmaceuticals Inc., a Canadian/U.S. specialty pharmaceutical company focused on the development of high-value cannabinoid drug therapies, today announced that the companies had executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology.

  9. Argonaut Manufacturing Services Set To Expand Drug Product Fill/Finish Capabilities With Significant Capital Investment 1/10/2023

    Argonaut Manufacturing Services (‘Argonaut’), a contract manufacturing organization (CMO) serving the life sciences, molecular diagnostics, and biopharma industries, today announced a capital investment led by majority shareholder Telegraph Hill Partners that will be focused on expansion at their Carlsbad, CA, manufacturing facilities.

  10. Oncorus Announces Research Collaboration With Daewoong Pharmaceutical For The Development Of Lipid Nanoparticle Formulations For mRNA Drug Candidates 1/4/2023

    Oncorus, Inc. (Nasdaq: ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle (LNP) formulations for mRNA drug candidates.